{Reference Type}: Journal Article
{Title}: Briefing on Investigational Chimeric Antigen Receptor T-Cell Immunotherapies in Pediatric Neoplasms.
{Author}: Stawicki B;Schacher T;Dushenkov A;Jungsuwadee P;
{Journal}: J Pharm Pract
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 8
暂无{DOI}: 10.1177/08971900241247619
{Abstract}: The promising results seen in the treatment of refractory hematologic malignancies with tisagenlecleucel (Kymriah), the pioneering Chimeric Antigen Receptor (CAR) T-cell immunotherapy, has stimulated a fast growth in research and clinical testing of novel CAR-T constructs, targets, and various generations of CAR T-cells. Pharmacists may receive inquiries about active clinical trials or may be contributing to the care of patients participating in these studies. This briefing discusses the on-going clinical trials that explore novel CAR T-cell immunotherapies in pediatric refractory malignancies of hematologic and solid organ origins. It can be valuable in assisting practitioners in navigating the rapidly evolving field of CAR T-cell immunotherapies.